OECD Consultation: sustainable access to innovative therapies

oecd logoAIM contributed to an OECD Online Consultation on sustainable access to innovative therapies. AIM is of the opinion that a broad political and societal discussion is needed about what a fair price is for pharmaceuticals. Discussions about fairness of prices require transparency of prices, transparency of costs made in the field of R&D  and require better insight in the efficacy and relative effectiveness of pharmaceuticals. The full contribution to the OECD consultation can be found here